Clinical trials: Proliferative Vitreoretinopathy, open to volunteers
Proliferative Vitreoretinopathy
Imaging and Predictive Modelling of Proliferative Vitreoretinopathy.
Patients with retinal detachment are at risk of recurrence and failure of surgery requiring multiple surgeries due to a condition called proliferative vitreoretinopathy (PVR).
- Trial name
- NCT07682025
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University College, London
Participants With Underactive Bladder (UAB)
A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)
The objective of this POC (Phase 2a) study is to evaluate the effect on Bladder Voiding Efficiency (BVE) as well as safety of SFG-02 transdermal formulation in participants with UAB.
- Trial name
- NCT07906106
- Testing
- SFG-02
- Where
- 16 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Juro Sciences Inc.
Retinal Detachment, Proliferative Vitreoretinopathy
Internal Limiting Membrane Peeling in Retinal Detachment Surgery
Despite advances in surgical techniques over the recent decades, proliferative vitreoretinopathy (PVR) remains the main obstacle to successful rhegmatogenous retinal detachment (RRD) repair, accounting for nearly 75% of all…
- Trial name
- IMPURITY (NCT05538156)
- Testing
- Control group, Intervention group
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy
Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment
Intravitreal topotecan exhibits strong anti-inflammatory, anti-proliferative, and anti-fibrotic properties, making it a promising option for preventing and treating proliferative vitreoretinopathy in rhegmatogenous retinal…
- Trial name
- TOPO-PT (NCT06818721)
- Testing
- Intravitreal topotecan, Retinal detachment surgery
- Where
- 2 sites in Canada
- Volunteers
- 394 people
- Sponsor
- Unity Health Toronto
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent…
- Trial name
- NCT06033703
- Testing
- Netarsudil Ophthalmic
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy
Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment
Disease or general study area: Uncomplicated rhegmatogenous retinal detachment (RRD) and risk of proliferative vittroretinopathy (PVR) Purpose and nature of the study: 1.
- Conditions
- Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy, Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
- Trial name
- Cohort-NHS (NCT07386678)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Retinal Detachment
REtinal Detachment Outcomes Study
Background: Few large randomized controlled trials provide strong evidence to guide surgical repair of primary rhegmatogenous retinal detachment (RRD) repair.
- Trial name
- REDOS (NCT05863312)
- Testing
- Pars plana vitrectomy, Pars plana vitrectomy with scleral buckle, Sulfur hexafluoride gas tamponade
- Where
- Canada
- Volunteers
- 560 people
- Sponsor
- CHU de Quebec-Universite Laval
Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy
Intravitreal topotecan has anti-inflammatory, anti-proliferative and anti-fibrotic activity that we hypothesize may exhibit high efficacy for the treatment of proliferative vitreoretinopathy (PVR) in patients with rhegmatogenous…
- Trial name
- TOPO-RD (NCT05523869)
- Testing
- Intravitreal topotecan, Pars plana vitrectomy with or without scleral buckle
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Unity Health Toronto
Proliferative Vitreoretinopathy, Proliferative Vitreo-Retinopathy
The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
The goal of this clinical trial is to evaluate the safety and efficacy of intravitreal topotecan for the treatment of patients with rhegmatogenous retinal detachment due to proliferative vitreoretinopathy (PVR) or resulting from…
- Conditions
- Proliferative Vitreoretinopathy, Proliferative Vitreo-Retinopathy, Rhegmatogenous Retinal Detachment
- Trial name
- NCT06425419
- Testing
- Topotecan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment
Prevention of ProliFerative Vitreoretinopathy With Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
I. Title Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial Today's Date: September 18, 2023 II.
- Trial name
- FIXER (NCT06541574)
- Testing
- Methotrexate Injection, Methotrexate Infusion
- Where
- United States
- Volunteers
- 860 people
- Sponsor
- Cincinnati Eye Institute, Southwest Ohio